Lyka Labs writes off ₹23 cr in subsidiary, posts annual loss
The nano-cap's Q4 impairment charge wipes out the value of its investment in Lyka BDR International, turning a full-year profit into a loss.
— 1 earlier story on Lyka Labs Ltd. →What's new
- Lyka Labs took a ₹23 crore impairment on its stake in Lyka BDR International, reducing its carrying value to zero.
- The standalone net loss for Q4 was ₹29.8 crore, compared to a profit of ₹7.9 crore in FY25.
- Annual revenue fell to ₹28 crore from ₹30.5 crore in the prior year.
Why this matters
For a company with a ₹220 crore market cap, a ₹23 crore write-down is material. It flips the annual result from profit to loss and signals that a key subsidiary is effectively worthless. The loss is now crystallised on the balance sheet.
What we're watching
- Any strategic plan for the subsidiary now valued at zero.
- The impact of the amalgamation scheme whose record date was set.
- Whether Lyka Labs can return to profitability without this drag.
The full read
Lyka Labs wrote off its entire ₹23 crore exposure to subsidiary Lyka BDR International. The impairment charge drove the company to a standalone net loss of ₹29.8 crore in Q4 and a full-year loss of ₹32.3 crore, erasing the ₹7.9 crore profit it posted in FY25. For a company with a ₹220 crore market cap, the charge alone is worth 10.5% of its equity value. Lyka BDR's continuous operational losses made the write-down inevitable; the subsidiary's carrying value is now zero. The other board action, setting a record date for shares under its amalgamation scheme, is procedural. The story here is the impairment. A nano-cap just told you a chunk of its balance sheet is worthless.
Questions answered
- Why did Lyka Labs record the impairment charge?
- The charge was taken because subsidiary Lyka BDR International has suffered continuous operational losses. The impairment reduced Lyka Labs' entire investment and loan exposure in the subsidiary to a carrying value of zero.
- How does this affect the annual results?
- For the full year, Lyka Labs swung from a profit of ₹7.9 crore in FY25 to a net loss of ₹32.3 crore in FY26. The ₹23 crore impairment is the primary driver of this reversal.
- What is the scale of the charge relative to the company?
- At ₹23 crore, the impairment is about 10.5% of Lyka Labs' ₹220 crore market capitalisation. It is a significant event for a nano-cap firm.
- What else did the board decide?
- The board also fixed a record date for issuing shares under its previously announced amalgamation scheme. The filing does not detail the scheme's terms.
Story so far
All notes on LYKALABS →- 25 May 2026 · 3:39 PM IST Lyka Labs writes off ₹23 cr in subsidiary, posts annual loss
- 42d ago Lyka Labs' Q4 loss is ₹29.77 cr. Most of it was already known.